Latest news with #MedXHealth
National Post
22-05-2025
- Business
- National Post
MedX Announces Further Closing of Non-Brokered Private Placement
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 7, 2025, announcing an Initial Closing, it has completed a further Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Further Closing comprised the issuance of 7,300,000 Units (as described below) and raised cash proceeds of $511,000, bringing the total amount raised so far to $1,456,000. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Further Closing(s) of the Placement will be subject to receipt of further subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Under this Non-Brokered Private Placement, the Company intends issue of up to a maximum of 35,714,858 Units at $0.07 per Unit ('Unit') to raise a Maximum amount of $2,500,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant (s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Qualified agents will receive a cash commission equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent's warrants (' Agent's Warrant(s) ') equal to 8% of subscriptions introduced by such agent(s). Each Agent's Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Article content Article content Funds raised in this Placement will be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. Article content About MedX Health Corp.: Article content MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Article content Article content Article content Article content Contacts Article content Article content Article content
National Post
15-05-2025
- Health
- National Post
MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSXV: MDX), the global leader in teledermatology solutions, is pleased to announce the signing of a commercial contract with Health Partners Group Ltd (' HPG ' or ' Health Partners Group '), the United Kingdom's largest occupational health services provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure® skin cancer screening platform. Article content Article content Following the pilot's success (11% of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure® skin cancer screening platform will be rolled out to Health Partners' clients across the UK and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy. Article content 'We are thrilled to deepen our relationship with Health Partners through this commercial agreement,' said Mike Druhan, President of Dermatological Services at MedX. 'This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast-track to a Dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace.' Article content With three million client employees served and 650+ corporate, government, and insurance clients, Health Partners Group is now poised to offer scalable, remote skin cancer screening as a standard part of their client employee health services. Article content 'The pilot validated the accuracy, speed, and accessibility of MedX's technology,' said Andrew Noble, CEO of Health Partners Group. 'Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include Skin Cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under 3 days from the current NHS wait time of between 5-9 months and helping safeguard the health of the UK's workforce.' Article content Skin cancer is among the most common forms of cancer in the UK, with over 220,000 cases diagnosed annually. According to the UK Cancer Alliance, outdoor workers face a 60% higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early and late-stage diagnoses. Article content The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when healthcare systems face growing demand and staffing pressures. Article content About Health Partners Group Ltd. Health Partners Group is the UK's leading occupational health and primary care provider, supporting corporate, government, insurance, and individual clients across the UK and Republic of Ireland. With over 1,300 staff and a robust technology platform, Health Partners Group delivers personalized and scalable health solutions. Visit: Article content About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. Visit: Article content Article content Article content Article content Article content Contacts Article content Article content Article content
National Post
06-05-2025
- Business
- National Post
MedX Announces Extension of Non-Brokered Private Placement
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 7, 2025, when it announced the Initial Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025, it has made application to the TSX Venture Exchange for an extension of 30 days to June 6, 2025, within which to effect further closings on this Private Placement. The Initial Closing, effective April 3, 2025, comprised the issuance of 13,500,000 Units (as described in detail in the Company's Press Release dated April 7, 2025) and raised cash proceeds of $945,000. With the extension of the final date for this Placement, it is anticipated that further Closings will take place, for up to a maximum of a further 22,214,285 Units at $0.07 per Unit, to raise up to a further $1,555,000. As previously announced, it is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Funds raised in this Placement will be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. Article content Article content About MedX Health Corp.: Article content MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit Article content Article content Article content Article content Article content Contacts Article content Article content Article content
